CAMP4 Therapeutics Corporation Common Stock (CAMP) is a publicly traded Healthcare sector company. As of November 17, 2026, CAMP trades at $4.11 with a market cap of $242.23M and a P/E ratio of -1.71. CAMP moved +3.89% today. Year to date, CAMP is -32.85%; over the trailing twelve months it is +0.80%. Its 52-week range spans $1.31 to $7.75. Analyst consensus is strong buy with an average price target of $9.00. Rallies surfaces CAMP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
CAMP4 Therapeutics Q3 loss per share misses analyst expectations: CAMP4 Therapeutics reported a Q3 loss of $0.37 per share, versus analyst expectations of $0.19. Its net loss widened mainly because of a non-cash loss from a change in derivative liability fair value; the company had $124.5 million in cash at quarter-end.
| Metric | Value |
|---|---|
| Price | $4.11 |
| Market Cap | $242.23M |
| P/E Ratio | -1.71 |
| EPS | $-2.32 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.75 |
| 52-Week Low | $1.31 |
| Volume | 186.91K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.22M |
| Net Income | $-107.24M |
| Gross Margin | 0.00% |
8 analysts cover CAMP: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $9.00.